A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
Open Access
- 25 January 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 77 (3), 459-476
- https://doi.org/10.1007/s00280-015-2931-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Determining the optimal dose in the development of anticancer agentsNature Reviews Clinical Oncology, 2014
- Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2014
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012Published by American Medical Association (AMA) ,2014
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialThe Lancet Oncology, 2013
- Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced MelanomaClinical Cancer Research, 2013
- A Time to Event Tutorial for PharmacometriciansCPT: Pharmacometrics & Systems Pharmacology, 2013
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic AnalysisThe Journal of Clinical Pharmacology, 2013
- The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision MakingThe Journal of Clinical Pharmacology, 2013
- Pharmacodynamic Models for Discrete DataClinical Pharmacokinetics, 2012
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialThe Lancet Oncology, 2012